This was first demonstrated experimentally by altering the expression of specific components (i.e. fibrillarin or dyskerin) of the ribonucleoprotein modification complexes leading to changes in the expression of key cancer genes including p53, p27, XIAP, Bcl-xL (28,73–75). This evidence concerns the gene TP53 and cancer.